List of Excipients in Branded Drug EQUATE EYE ALLERGY RELIEF DROPS

« Back to Dashboard

Generic Drugs Containing EQUATE EYE ALLERGY RELIEF DROPS

Company	Ingredient	NDC	Excipient
Wal-Mart Stores Inc	naphazoline hydrochloride, pheniramine maleate	49035-874	BENZALKONIUM CHLORIDE
Wal-Mart Stores Inc	naphazoline hydrochloride, pheniramine maleate	49035-874	BORIC ACID
Wal-Mart Stores Inc	naphazoline hydrochloride, pheniramine maleate	49035-874	EDETATE DISODIUM
Wal-Mart Stores Inc	naphazoline hydrochloride, pheniramine maleate	49035-874	HYPROMELLOSE

What are the Most Frequently-Used Excipients in EQUATE EYE ALLERGY RELIEF DROPS?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	BORIC ACID
1	EDETATE DISODIUM
1	HYPROMELLOSE

Equate Eye Allergy Relief Drops: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: October 4, 2026

Equate Eye Allergy Relief Drops is an OTC ophthalmic product marketed under Walmart’s private-label brand. The product uses ketotifen fumarate 0.035%, equivalent to ketotifen 0.025%, as the active ingredient for temporary relief of itchy eyes associated with allergies. Its commercial position depends less on active-ingredient exclusivity than on low-cost manufacturing, preservative control, container performance, retail distribution and opportunities for differentiated formulations.[1]

The publicly identified formulation uses purified water, glycerin, benzalkonium chloride and pH-adjusting agents, including hydrochloric acid and sodium hydroxide.[1] This is a conventional preserved multidose ophthalmic formulation. Its principal commercial weakness is the use of benzalkonium chloride, which creates an opportunity for preservative-free, sensitive-eye and premium packaging variants.

What is Equate Eye Allergy Relief Drops?

Equate Eye Allergy Relief Drops is a ketotifen ophthalmic solution for OTC treatment of ocular itching caused by allergic conjunctivitis.

Attribute	Publicly identified product information
Brand	Equate
Retailer	Walmart
Dosage form	Ophthalmic solution
Active ingredient	Ketotifen fumarate 0.035%
Equivalent active strength	Ketotifen 0.025%
Therapeutic category	Ophthalmic antihistamine and mast-cell stabilizer
Indication	Temporary relief of itchy eyes due to allergies
Route	Topical ophthalmic
Preservative	Benzalkonium chloride
Key excipients	Glycerin, purified water, hydrochloric acid and sodium hydroxide
Regulatory pathway	OTC ophthalmic drug labeling and monograph-based framework
Prescription status	OTC
Biosimilar relevance	None

Ketotifen has a dual pharmacologic profile. It blocks histamine H1 receptors and stabilizes mast cells. The formulation therefore does not require a novel delivery mechanism to compete with prescription products, but it must maintain sterility, chemical stability, dosing accuracy and acceptable ocular tolerability.[1,2]

What excipients are used in Equate Eye Allergy Relief Drops?

The listed excipients are functional rather than proprietary. They support isotonicity, comfort, pH control, preservation and product stability.

Excipient	Primary formulation function	Commercial significance
Purified water	Vehicle	Must meet pharmaceutical water and microbiological quality requirements
Glycerin	Humectant and tonicity contributor	Can improve ocular comfort and reduce the perception of dryness
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but may create tolerability concerns with frequent use
Hydrochloric acid	pH adjustment	Used to bring the solution within the target pH range
Sodium hydroxide	pH adjustment	Used with acid to control final pH

The formulation is technically straightforward. The major development challenge is not excipient novelty but balancing preservative efficacy, ocular comfort, active stability, container compatibility and manufacturing cost.

Why is glycerin commercially important?

Glycerin can contribute to osmolarity and provide a humectant effect. In an allergy product, that function supports a more comfortable user experience, especially for consumers who experience dryness together with itching.

Glycerin is also inexpensive, widely available and familiar to ophthalmic manufacturers. It is unlikely to create meaningful patent differentiation on its own. Its value lies in formulation optimization, not exclusivity.

What role does benzalkonium chloride play?

Benzalkonium chloride, commonly abbreviated BAK, protects multidose ophthalmic products against microbial contamination after opening. It is a standard preservative in eye drops, but repeated exposure can irritate the ocular surface in some users.[3]

The BAK concentration disclosed in the public label is approximately 0.01%. A preserved multidose bottle has cost and convenience advantages, but it is less differentiated than a preservative-free presentation. Competitors can target consumers with dry eye, contact-lens use, chronic allergy symptoms or sensitivity to preserved products.

How do pH-adjusting agents affect the product?

Hydrochloric acid and sodium hydroxide do not function as therapeutic ingredients. They allow the manufacturer to adjust final pH after the active ingredient and excipients are dissolved.

Their commercial importance is indirect. pH affects:

• Ketotifen chemical stability.
• Ocular comfort.
• Preservative performance.
• Solubility and clarity.
• Container-closure compatibility.
• Shelf life.

A company seeking to develop a competing product would need to validate the complete formulation rather than simply copy the listed excipient categories. Small changes in pH, buffer capacity, ionic strength or preservative concentration can affect stability and tolerability.

What formulation opportunities exist for competing ketotifen eye drops?

The strongest commercial opportunities are formulation and packaging improvements rather than new active ingredients.

Preservative-free ketotifen

A preservative-free product could target consumers who experience ocular-surface irritation from BAK or who use allergy drops repeatedly during pollen seasons. Single-dose vials are the most established approach, although they increase packaging, filling and distribution costs.

Potential advantages include:

• Better positioning for sensitive eyes.
• Greater compatibility with frequent use.
• Reduced concern about preservative exposure.
• Premium pricing potential.

The principal disadvantages are higher unit cost, more packaging material, greater filling complexity and possible waste from single-use containers.

Preservative-free multidose packaging

Preservative-free multidose systems use specialized valves, filters or container designs to limit microbial ingress. They can provide convenience closer to a conventional bottle, but the device becomes a material part of the product’s regulatory and intellectual-property strategy.

A company pursuing this route would need to establish:

• Microbial ingress protection.
• Delivered-dose consistency.
• Priming and re-priming performance.
• Compatibility between the formulation and the device.
• Container-closure integrity.
• In-use stability.

This area offers stronger differentiation than simply changing glycerin concentration or using a different pH adjuster.

Contact-lens-compatible positioning

A formulation intended for use by contact-lens wearers could address a large consumer need, but the product would require precise labeling and safety support. The presence of BAK can complicate contact-lens positioning because preservatives may be absorbed by some lens materials or increase irritation.

A commercial strategy could include a preservative-free presentation with explicit instructions for lens removal and reinsertion. Such claims would need to be supported by labeling, compatibility testing and applicable FDA requirements.

Lubricating allergy formulation

A ketotifen formulation could combine antihistamine activity with an ocular lubricant or comfort-oriented excipient system. Glycerin already provides some humectant and tonicity value, but a differentiated product could investigate additional lubricating polymers.

Potential excipient classes include:

• Polyethylene glycol.
• Propylene glycol.
• Hypromellose.
• Hydroxypropyl guar.
• Carboxymethylcellulose.

The commercial tradeoff is increased viscosity, possible transient blurring, altered drop size and more complicated stability testing. A thicker product may improve comfort but could reduce consumer acceptance if it affects vision immediately after dosing.

What FDA regulatory status applies to Equate Eye Allergy Relief Drops?

The product is an OTC ophthalmic drug marketed using a standardized ketotifen active ingredient and consumer labeling framework. Ketotifen fumarate ophthalmic products are recognized for temporary relief of itchy eyes associated with allergies.[1,2]

The regulatory strategy is important because an OTC monograph-style product generally does not depend on an innovator NDA for market access. A compliant competitor can enter without obtaining a license from Walmart or the label owner, subject to applicable FDA requirements, manufacturing controls, labeling rules and product-specific obligations.

The product remains subject to:

• Current good manufacturing practice requirements.
• Drug establishment registration and listing.
• Ophthalmic sterility requirements.
• Stability testing.
• Container-closure controls.
• Adverse-event reporting.
• OTC labeling requirements.
• FDA inspection and enforcement authority.

What is the Orange Book status of Equate Eye Allergy Relief Drops?

Equate Eye Allergy Relief Drops does not have the commercial profile of an NDA-backed branded prescription product. Its market position is based on OTC drug regulation and private-label distribution rather than Orange Book exclusivity.

The practical consequences are:

Issue	Commercial implication
Orange Book patent listing	No publicly identified product-specific Orange Book patent position is central to the product
Paragraph IV challenge	Not the normal entry mechanism for this OTC private-label product
Generic approval strategy	Competitors generally pursue compliant OTC marketing rather than an ANDA against Equate
Exclusivity	No identified product-specific NCE or NDA exclusivity protecting the private-label product
Patent leverage	More likely to arise from packaging, device or manufacturing patents than from the listed excipients

The absence of an Orange Book barrier does not eliminate intellectual-property risk. A competitor could still face patents covering preservative-free containers, dispensing valves, manufacturing processes, sterile filling systems or formulation combinations.

When does Equate Eye Allergy Relief Drops lose exclusivity?

The product does not appear to rely on a product-specific period of market exclusivity comparable to an NCE, orphan-drug or pediatric-exclusivity period. The active ingredient is an established OTC therapeutic, and the disclosed excipients are conventional.

Accordingly, commercial entry risk is driven by:

1. FDA compliance.
2. Manufacturing capacity.
3. Retail access.
4. Product quality.
5. Packaging differentiation.
6. Trademark and trade-dress boundaries.
7. Any third-party formulation or device patents.

A competing manufacturer can generally pursue its own ketotifen ophthalmic product without waiting for Equate-specific patent expiry, provided it avoids protected branding and complies with regulatory requirements.

How strong is the patent estate for the excipient strategy?

The disclosed excipient combination has low apparent patent strength as a standalone composition. Purified water, glycerin, benzalkonium chloride and pH-adjusting agents are widely used pharmaceutical materials.

IP area	Apparent strength	Reason
Basic ketotifen solution	Low	Established active and conventional dosage form
Glycerin-containing vehicle	Low	Common excipient use
BAK-preserved multidose formulation	Low to moderate	Potential process or concentration-specific claims, but limited novelty from the concept alone
Preservative-free formulation	Moderate	Stronger if tied to a defined stability or tolerability profile
Preservative-free multidose device	Moderate to high	Device architecture and microbial-barrier claims may be protectable
Container-closure system	Moderate	Patent value depends on specific design and performance
Manufacturing process	Moderate	Potential protection for sterile filling, mixing or stability controls
Trade dress and brand	Separate from patent strength	Retail recognition can still deter confusingly similar products

The highest-value patent strategy would likely combine formulation and device claims. A claim directed only to “ketotifen plus glycerin in purified water” would face substantial prior-art and obviousness risk. Claims tied to a defined preservative-free multidose system, improved stability, reduced irritation or specific delivered-dose performance would have greater commercial relevance.

What patent litigation and Paragraph IV risks affect the product?

No product-specific Paragraph IV litigation is central to the publicly identified Equate OTC product. Paragraph IV litigation is generally associated with ANDA applicants challenging patents listed against an approved NDA in the Orange Book. That framework does not normally describe a private-label OTC ketotifen product marketed under a monograph-based approach.

Potential disputes could instead involve:

• Patent infringement claims against a dispenser or container.
• Trade-dress claims involving bottle design or labeling.
• Trademark disputes involving “Equate” or confusingly similar branding.
• Manufacturing-process patents.
• Contract disputes involving Walmart, the labeler or a contract manufacturer.
• Regulatory enforcement involving sterility, labeling or product quality.

No biosimilar risk applies. Ketotifen is a small-molecule drug, not a biologic. Competitive pressure comes from other OTC ketotifen products, prescription allergy drops, generic ophthalmic products and non-drug allergy treatments.

Which companies compete with Equate Eye Allergy Relief Drops?

Competition exists at three levels.

Private-label retailers

Retailers such as CVS, Walgreens, Target and Amazon may market ketotifen or alternative allergy eye drops under store brands. Their competitive advantages are shelf placement, price promotion, loyalty programs and control of retail data.

Branded OTC products

Well-known allergy-eye brands compete through advertising, consumer recognition and broader product portfolios. A branded product may command a higher price even when its active ingredient and excipient architecture are similar.

Prescription and alternative therapies

Prescription antihistamine/mast-cell stabilizer products, including olopatadine and other ophthalmic agents, can compete for patients seeking longer duration, physician-directed treatment or a different tolerability profile.

Competitive factor	Equate position	Opportunity for competitors
Price	Strong through private-label economics	Difficult to beat without scale
Brand recognition	Strong within Walmart	Build pharmacy or specialist brand trust
Formulation novelty	Limited publicly disclosed differentiation	Offer preservative-free or comfort-focused products
Distribution	Strong Walmart access	Use pharmacy, e-commerce and specialty channels
Packaging	Conventional multidose format	Differentiate through unit-dose or advanced multidose systems
Consumer targeting	Broad allergy market	Target contact-lens wearers and sensitive-eye users

What licensing and manufacturing opportunities exist?

The most attractive licensing opportunities are likely to involve delivery systems and contract manufacturing rather than the basic ketotifen formulation.

Potential deal structures include:

• Licensing a preservative-free multidose dispenser.
• Contract manufacturing for private-label retailers.
• Supply agreements for ophthalmic-grade ketotifen fumarate.
• Co-development of single-dose packaging.
• Regional commercialization rights.
• Technology transfer for sterile ophthalmic filling.
• Packaging supply agreements with device manufacturers.

Manufacturing is a meaningful barrier because ophthalmic products require validated sterile processes, controlled environments, qualified components and reliable microbiological testing. The active ingredient is not the primary bottleneck. The more defensible capabilities are sterile filling, container-closure integrity, in-use stability and high-volume low-defect production.

What revenue exposure and commercial upside exist?

Equate’s revenue is not separately disclosed in Walmart’s public financial reporting. The product should be evaluated as part of Walmart’s broader private-label health and wellness business rather than as a separately reported asset.

The commercial opportunity is strongest in four segments:

1. Low-cost seasonal allergy treatment.
2. Preservative-sensitive consumers.
3. Contact-lens users.
4. E-commerce and subscription replenishment.

A preservative-free product could support premium pricing, but the economic model must absorb higher packaging and manufacturing costs. The basic preserved product is better suited to high-volume retail, while a device-enabled preservative-free product is better suited to margin expansion and targeted consumer segmentation.

Key Takeaways

• Equate Eye Allergy Relief Drops is a private-label OTC ketotifen ophthalmic solution.
• The disclosed excipient strategy is conventional and includes purified water, glycerin, benzalkonium chloride and pH-adjusting agents.
• BAK preservation enables multidose packaging but creates a clear opportunity for preservative-free competitors.
• The basic formulation has limited apparent patent strength because its ingredients and dosage form are established.
• The strongest IP opportunities are in preservative-free multidose devices, container systems, stability improvements and manufacturing processes.
• Paragraph IV litigation and biosimilar competition are not central to this product.
• Walmart’s principal advantages are retail distribution, private-label pricing and consumer access.
• The most credible commercial extensions are preservative-free single-dose units, advanced multidose packaging, contact-lens-oriented products and lubricant-enhanced formulations.
• Revenue is not separately disclosed, so exposure should be assessed through Walmart’s broader OTC and private-label health business.

FAQs

Can another company sell a ketotifen eye drop similar to Equate?

Yes. A competitor can generally market its own compliant ketotifen ophthalmic product without obtaining a license from Walmart, subject to FDA requirements and third-party intellectual-property rights.

Is benzalkonium chloride the main weakness of the Equate formulation?

It is the clearest formulation-based differentiation point. BAK supports multidose sterility but can be less attractive to consumers with ocular-surface sensitivity or frequent-use needs.

Would a preservative-free ketotifen product qualify for premium pricing?

It could, particularly if paired with single-dose convenience, sensitive-eye positioning or an advanced multidose dispenser. Premium pricing would depend on packaging cost, clinical support and retail positioning.

Are excipient patents likely to block a competing ketotifen product?

Basic excipient selection is unlikely to create a strong barrier. More meaningful risk could arise from patents covering a specific formulation, preservative-free system, dispenser or manufacturing method.

Is Equate Eye Allergy Relief Drops a biosimilar product?

No. Ketotifen is a small-molecule active ingredient. The relevant competition is from other OTC and prescription ophthalmic products, not biosimilars.

References

1. DailyMed. (n.d.). Equate Eye Allergy Relief: Ketotifen fumarate ophthalmic solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph for ophthalmic drug products for temporary relief of allergic conjunctivitis symptoms. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Ophthalmic drug products and preservative considerations. https://www.fda.gov/industrial-resources/prescription-drug-labeling-resources/ophthalmic-drug-products-sterility-and-quality-considerations